Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
Authors
Keywords
-
Journal
BMC GASTROENTEROLOGY
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-08
DOI
10.1186/s12876-020-01332-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases
- (2018) Brian G. Feagan et al. Clinical Gastroenterology and Hepatology
- P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
- (2018) Stefan Schreiber et al. INFLAMMATORY BOWEL DISEASES
- Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study
- (2018) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses—Part I
- (2018) Simon R Knowles et al. INFLAMMATORY BOWEL DISEASES
- OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
- (2018) D Faleck et al. Journal of Crohns & Colitis
- OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
- (2018) M Bohm et al. Journal of Crohns & Colitis
- P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
- (2018) B Bressler et al. Journal of Crohns & Colitis
- DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
- (2018) D Lukin et al. Journal of Crohns & Colitis
- Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
- (2018) Stefan Schreiber et al. JOURNAL OF GASTROENTEROLOGY
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
- (2017) Fernando Magro et al. Journal of Crohns & Colitis
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
- (2017) Siew C Ng et al. LANCET
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease
- (2015) Jason P. Gordon et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Crohn’s Disease Evaluation and Treatment: Clinical Decision Tool
- (2014) William J. Sandborn GASTROENTEROLOGY
- TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
- (2014) Romain Altwegg et al. MEDIATORS OF INFLAMMATION
- Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort
- (2014) Rebecca Hein et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease
- (2010) Michael D. Kappelman et al. INFLAMMATORY BOWEL DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now